North America Non-Alcoholic Steatohepatitis Market

The North America non-alcoholic steatohepatitis market is expected to reach US$ 12,963.42 million by 2028 from US$ 838.07 million in 2021. The market is estimated to grow at a CAGR of 47.9% from 2021 to 2028.

Non-alcoholic steatohepatitis (NASH) is a potentially fatal illness that causes extensive scarring and cirrhosis in the liver. Non-alcoholic fatty liver disease (NAFLD) is North America's most common chronic liver disease. NASH is a progressive form of NAFLD, which is gradually becoming the major cause of end-stage liver diseases and liver transplantation. According to the data published by the Global Liver Institute on June 12, 2019, non-alcoholic steatohepatitis (NASH) has been called an epidemic. Furthermore, it is a progressive type of non-alcoholic fatty liver disease (NAFLD) that affects over ~115 million people and by 2030, 357 million people are expected to be affected. Obesity, type 2 diabetes, and hyperlipidemia are substantial risk factors for NAFLD and NASH: more than ~70% of people are obese, ~75% have type 2 diabetes, and 20-80% have hyperlipidemia. NASH, if left untreated, can progress to cirrhosis, liver cancer, and the need for a liver transplant. As per the data published by the American Liver Foundation, NAFLD is the most common chronic liver disease in the US. It is projected that ~25% of adults in the US have NAFLD, out of which ~20% have NASH, which is 5% of adults in the US. According to the NASH Education Program, NASH prevalence is expected to increase by 63% between 2015 and 2030. Between 2020 and 2025, NASH is predicted to become the major cause of liver transplantation in the US. The American Association for the Study of Liver Diseases published a report in 2018 using Markov modeling to forecast NAFLD disease by 2030 and observed that the prevalence of NAFLD and NASH cases are forecasted to increase by 21% and 63%, respectively, providing 33.5% and 27% prevalence rate of NAFLD and NASH in adults, respectively. Despite its increasing prevalence, NAFLD/NASH remains an under-recognized condition, and early detection is critical to reducing the risk of progression and its associated consequences.Thus, the growing prevalence of NASH is expected to drive the non-alcoholic steatohepatitis (NASH) market.The North America Non-Alcoholic Steatohepatitis market is expected to grow at a good CAGR during the forecast period.

North America Non-Alcoholic Steatohepatitis Revenue and Forecast to 2028 (US$ Million)

  

North America Non-Alcoholic Steatohepatitis Market Segmentation   

The North America Non-Alcoholic Steatohepatitis market segmented into product, application, sales channel and country. Based on product type the North America Non-Alcoholic Steatohepatitis  market is segmented into vitamin e and pioglitazone, ocaliva, elafibranor, selonsertib,cenicriviroc and others. The selonsertib & cenicriviroc segment is expected to be the fastest growing segment over the forecaste period .Based on application the North America Non-Alcoholic Steatohepatitis market segmented into treatment and diagnosis. The treatment segment is dominated North America Non-Alcoholic Steatohepatitis market in 2020. Based on sales channel the North America Non-Alcoholic Steatohepatitis market segmented into hospital pharmacy, online provider, and retail pharmacy. The retail pharmacy segment is dominated North AmericaNon-Alcoholic Steatohepatitis market in 2020. Based on country, the North America Non-Alcoholic Steatohepatitis market is segmented into the US, Mexico, and Canada. The US dominated the North America non-alcoholic steatohepatitis market in 2020.

Cadila Pharmaceutical, Intercept Pharmaceutical, Novartis AG, Galmed Pharmaceutical, GENFIT, Prometheus Laboratories, Siemens Healthineers AG, and Laboratory Corporation of America are among the leading companies in North America non-alcoholic steatohepatitis market.